Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
The U.S. Centers for Medicare & Medicaid Services has approved coverage for the Dexcom G7, a continuous glucose monitoring system designed for diabetes management. Launching on February 17, 2023, the G7 is touted as the most accurate CGM, eliminating routine fingersticks and offering real-time glucose readings. This approval cements Dexcom's position as a leading CGM provider, making the G7 accessible to Medicare patients. The device features a 30-minute sensor warm-up, smaller design, and improved app integration, enhancing user experience and diabetes management.
DexCom reported its Q4 and full year 2022 results, highlighting a 17% revenue increase to $815.2 million in Q4 and 19% growth for the year, totaling $2.91 billion. U.S. revenue grew by 17% and international by 15% (27% organic). GAAP operating income rose to $125.4 million (15.4% margin), while non-GAAP reached $172.1 million (21.1% margin). The company launched the Dexcom G7 CGM system and plans for a revenue guidance of $3.35 - 3.49 billion for 2023, signifying 15-20% growth. DexCom ended 2022 with $2.46 billion in cash and equivalents.
Dexcom, Inc. (NASDAQ:DXCM) has launched the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System, announced through a new Super Bowl commercial featuring Nick Jonas. The G7 promises to be the most accurate and user-friendly CGM on the market, helping diabetes patients improve their health management without fingersticks. The campaign aims to raise awareness among the 4.8 million insulin-dependent Americans, highlighting how the G7 can lower A1C levels and enhance time in range. Approximately 3.3 million viewers who currently do not use CGM have coverage options, making awareness crucial for better diabetes management.
Mednow Inc. (OTCQX: MDNWF) has launched an enhanced Virtual Diabetes Management program that integrates Dexcom G6 real-time continuous glucose monitoring (rtCGM) supplies and diabetes support services. This program offers convenient home delivery and access to certified diabetes educators and clinical pharmacists for personalized care. Initially available in Ontario and British Columbia from early February, the integration aims to improve accessibility and management for diabetes patients. The partnership with Dexcom aims to leverage their technology to enhance patient care and support effective diabetes management.
DexCom, Inc. (NASDAQ:DXCM) announced its plans to release financial results for the fourth quarter and full year 2022 on February 9, 2023, post market close. The management will discuss the results in a conference call at 4:30 p.m. ET on the same day, which will also be available via webcast. This financial report is crucial for investors and stakeholders to gauge the company's performance in the diabetes care technology sector.
Dexcom, Inc. (NASDAQ: DXCM) announced an expansion of coverage for its Dexcom G6 real-time continuous glucose monitoring (rtCGM) system under the Non-Insured Health Benefits (NIHB) program. This change allows all clients living with type 1 diabetes, beyond the existing restriction for ages 2 to 19, to receive coverage. The initiative aims to improve health outcomes for Indigenous communities, who are disproportionately affected by diabetes, by providing greater access to essential healthcare technology. The Dexcom G6 system aids in better glucose control and reduces the risk of diabetes-related complications.
DexCom, Inc. (NASDAQ: DXCM) has appointed Teri Lawver as the chief commercial officer, a newly created role responsible for global sales, marketing, and customer experience. Ms. Lawver brings over 20 years of leadership experience from Johnson & Johnson, where she successfully grew the immunology business from $11 billion to $16 billion. CEO Kevin Sayer praised her ability to drive growth in the healthcare sector. Ms. Lawver aims to leverage Dexcom's market opportunities and technology to expand the reach of continuous glucose monitoring solutions.
DexCom, Inc. (NASDAQ: DXCM) expects preliminary revenue of at least
DexCom, Inc. (NASDAQ:DXCM) announced that CEO Kevin Sayer will present at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023, starting at 2:15 PM EST. The presentation will be webcast live and made available for later viewing on the Dexcom Investor Relations website.
DexCom focuses on diabetes management through its innovative continuous glucose monitoring (CGM) systems, serving users globally from its headquarters in San Diego, California.
Dexcom, Inc. (NASDAQ: DXCM) has launched a new Digital Diabetes Care Program in partnership with Green Shield and The Health Depot. This initiative will provide Green Shield plan members access to the Dexcom G6 real-time continuous glucose monitoring (rtCGM) system along with virtual diabetes management support. Benefits include automated product shipments, preferred pricing, direct billing, and co-payment assistance for Dexcom supplies. The program aims to enhance diabetes management and improve health outcomes by providing personalized support and clinical consultations.
FAQ
What is the current stock price of Dexcom (DXCM)?
What is the market cap of Dexcom (DXCM)?
